Core Insights - Quantum BioPharma Ltd. is facing allegations of stock market manipulation, which has led to a USD $700 million lawsuit against CIBC and RBC, two of Canada's largest banks [2][3]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, including its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [4]. - The company retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of a product called unbuzzd™, and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty rate drops to 3% [4]. Industry Context - The investigative series by CTV News highlights the illegal practice of "stock spoofing," which is a form of market manipulation that affects retail investors and can derail important research and development efforts in the biopharmaceutical sector [2][3].
Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5